Literature DB >> 24054815

The right to participate in high-risk research.

David Shaw1.   

Abstract

Mesh：

Year:  2013        PMID： 24054815     DOI： 10.1016/S0140-6736(13)61575-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  Deliberate Microbial Infection Research Reveals Limitations to Current Safety Protections of Healthy Human Subjects.

Authors:  David L Evers; Carol B Fowler; Jeffrey T Mason; Rebecca K Mimnall
Journal:  Sci Eng Ethics       Date:  2014-08-24       Impact factor: 3.525

2.  Putting patients on research ethics committees.

Authors:  David Shaw; Bernice Elger
Journal:  J R Soc Med       Date:  2014-08-01       Impact factor: 5.344

3.  The Role of Inclusion Benefits in Ethics Committee Assessment of Research Studies.

Authors:  Stuart Rennie; Suzanne Day; Allison Mathews; Adam Gilbertson; Winfred K Luseno; Joseph D Tucker; Gail E Henderson
Journal:  Ethics Hum Res       Date:  2019-05

4.  SARS-CoV-2 challenge studies: ethics and risk minimisation.

Authors:  Susan Bull; Euzebiusz Jamrozik; Ariella Binik; Michael J Parker
Journal:  J Med Ethics       Date:  2020-09-25       Impact factor: 2.903

5.  Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment.

Authors:  Gail E Henderson; Holly L Peay; Eugene Kroon; Rosemary Jean Cadigan; Karen Meagher; Thidarat Jupimai; Adam Gilbertson; Jill Fisher; Nuchanart Q Ormsby; Nitiya Chomchey; Nittaya Phanuphak; Jintanat Ananworanich; Stuart Rennie
Journal:  J Med Ethics       Date:  2017-11-10       Impact factor: 2.903

Review 6.  Human infection challenge studies in endemic settings and/or low-income and middle-income countries: key points of ethical consensus and controversy.

Authors:  Euzebiusz Jamrozik; Michael J Selgelid
Journal:  J Med Ethics       Date:  2020-05-07       Impact factor: 2.903
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.